TLRA Telaria Inc

SCHEDULE 13D/A

SCHEDULE 13D/A

SCHEDULE 13D/A

This Amendment No. 8 ("Amendment No. 8") amends and supplements the statements on Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on March 7, 2018 (the "Original Schedule 13D"), Amendment No 1 to the Original Schedule 13D filed with the SEC on May 30, 2018 ("Amendment No. 1"), Amendment No. 2 to the Original Schedule 13D filed with the SEC on August 22, 2018 ("Amendment No. 2"), Amendment No. 3 filed with the SEC on November 13, 2018 ("Amendment No.3"), Amendment No. 4 filed with the SEC on December 28, 2018 ("Amendment No. 4"), Amendment No. 5 filed with the SEC on August 30, 2019 ("Amendment No. 5"), Amendment No. 6 filed with the SEC on January 10, 2020 ("Amendment No. 6") and Amendment No. 7 filed with the SEC on February 12, 2020 ("Amendment No. 7")  and together with the Original Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No.4, Amendment No. 5, Amendment No. 6 and this Amendment No. 8, the ("Schedule 13D"), with respect to the Common Stock, par value $0.0001 per share (the "Common Stock") of Telaria, Inc., a Delaware corporation (the "Issuer").  Capitalized terms used herein and not otherwise defined in this Amendment No. 8 have the meanings set forth in the Schedule 13D.  This Amendment No 8 amends Items 3, 5 and 6 as set forth below.

Item 3. Source and Amount of Funds or Other Considerations

Shares reported represent 2,021,345 shares of Common Stock of the Issuer.

The Reporting Persons used a total of approximately $7,400,645 (including commissions, if any) to acquire the Common Stock reported in this Schedule 13D. The Common Stock was purchased with the investment capital of the Fund and certain other private investments funds advised by Edenbrook.

Item 5. Interest in Securities of the Issuer

(a) As of the date hereof, (i) Edenbrook and Mr. Brolin may be deemed to be the beneficial owners of 2,021,345 shares of Common Stock, constituting 4.25% of the shares of Common Stock, based upon 47,537,025 shares of Common Stock outstanding as of February 11, 2020, as reported in the Issuer's Definitive Proxy Statement relating to merger or acquisition filed by the Issuer on February 13, 2020, and (ii) the Fund may be deemed to be the beneficial owner of 1,690,507 shares of  Common Stock, constituting 3.56% of the shares of Common Stock, based upon 47,537,025 shares of Common Stock outstanding as of February 11, 2020, as reported in the Issuer's Definitive Proxy Statement relating to merger or acquisition filed by the Issuer on February 13, 2020.

(b) Edenbrook and Mr. Brolin have the sole power to vote or direct the vote of 0 shares of Common Stock; has the shared power to vote or direct the vote of 2,021,345 shares of Common Stock; has the sole power to dispose or direct the disposition of 0 shares of Common Stock; and has the shared power to dispose or direct the disposition of 2,021,345 shares of Common Stock.

 The Fund has the sole power to vote or direct the vote of 0 shares of Common Stock; has the shared power to vote or direct the vote of 1,690,507 shares of Common Stock; has the sole power to dispose or direct the disposition of 0 shares of Common Stock; and has the shared power to dispose or direct the disposition of 1,690,507 shares of Common Stock.

(c)  The transactions by the Reporting Persons in the securities of the Issuer since the last filing are set forth in Schedule A.  All such transactions were carried out in open market transactions.

(d) No person other than the Reporting Persons and the private investments funds advised by Edenbrook are known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the shares of Common Stock held by the Fund and the other private investment funds advised by Edenbrook.             

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

The Reporting Persons wrote 4,100 put option contracts expiring in 2020 which provide that the Reporting Persons will be required to purchase additional shares of Common Stock if the counterparty thereto exercises such put option. In addition, the Reporting Persons wrote 7,510 call option contracts expiring in 2020, which provide that the Reporting Persons have the obligation to sell shares of Common Stock at the strike price if the counterparty thereto exercises such call option.

Except as described in this Item 6, none of the Reporting Persons has any contracts, arrangements, understandings or relationships with respect to the securities of the Issuer.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

EDENBROOK LONG ONLY VALUE FUND, LP

BY: Edenbrook Capital Partners, LLC

Its General Partner

Exhibit A

Schedule of Transactions in Shares by Private Funds Advised by Edenbrook